A critical review on the status of clinical practice guideline development in China and an introduction of the Protocol of'2018 Chinese Society of Endocrinology Guideline for Diagnosis and Management of Hyperuricemia and Gout'
10.3760/cma.j.issn.1000-6699.2019.03.001
- VernacularTitle:中国临床指南现状分析及《中国高尿酸血症与痛风诊治指南(2018)》制定介绍
- Author:
Mingshu SUN
1
;
Yiming MU
;
Jiajun ZHAO
;
Weiping TENG
;
Changgui LI
Author Information
1. 青岛大学附属医院风湿免疫科 266003
- Keywords:
Guideline;
Hyperuricemia;
Gout;
Critical review
- From:
Chinese Journal of Endocrinology and Metabolism
2019;35(3):181-184
- CountryChina
- Language:Chinese
-
Abstract:
In 2013,the Chinese Society of Endocrinology published the'Management ofhyperuricemia and gout:Chinese experts consensus'.In the following five years,a large number of basic researches,clinical studies,and epidemiological results had emerged and need to be popularized in order to improve the understanding and standardizing management of these conditions in general physicians.On the other hand,the methodology of developing clinical guidelines has become more and more scientific,standardized and international.Therefore,based on the 2013 version of the consensus,Chinese Society of Endocrinology decided to develop a guideline for the diagnosis and management of hyperuricemia and gout under standardized methods and procedures of evidence-based clinical practice guidelines.This article will give a review of the status of clinical practice guideline development in China and explain the methods and procedures followed when developing this guideline.We hope this work may provide some useful recommendations for other developers to draft evidence-based clinical practice guidelines.
